Urology
Volume 75, Issue 2 , Pages 467-471 , February 2010

The Importance of Serum Prostate-specific Antigen Testing Frequency in Assessing Biochemical and Clinical Failure After Prostate Cancer Treatment

Presented at American Brachytherapy Society annual meeting May 2008.

  • Jay P. Ciezki

      Affiliations

    • Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio
    • Corresponding Author InformationReprint requests: Jay P. Ciezki, M.D., Department of Radiation Oncology, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195
    • ,
  • Chandana A. Reddy

      Affiliations

    • Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Andrew J. Stephenson

      Affiliations

    • Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Kenneth Angermeier

      Affiliations

    • Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio
    • ,
  • James Ulchaker

      Affiliations

    • Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Andrew Altman

      Affiliations

    • Department of Urology, Kaiser Permanente, Cleveland, Ohio
    • ,
  • Nabil Chehade

      Affiliations

    • Department of Urology, Kaiser Permanente, Cleveland, Ohio
    • ,
  • Eric A. Klein

      Affiliations

    • Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio

Received 19 June 2009 ,Accepted 19 August 2009.

References 

  1. Cox J, Grignon D, Kaplan R, et al. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  2. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  3. Schellhammer P, Cockett A, Boccon-Gibod L, et al. Assessment of endpoints for clinical trials for localized prostate cancer. Urology. 1997;49(suppl 4A):27–38
  4. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006;24:3973–3978
  5. Roach M, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression radiation therapy oncology group 9413. J Clin Oncol. 2003;21:1904–1911
  6. NCCN Practice Guidelines in Oncology -v.2.2007 Prostate Cancer (National Comprehensive Cancer Network, Inc., 2007). http://www.nccn.org/professionals/physicians_gls/PDFprostate.pdfAccessed April 9, 2007
  7. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035–2041

PII: S0090-4295(09)02430-3

doi: 10.1016/j.urology.2009.08.051

Urology
Volume 75, Issue 2 , Pages 467-471 , February 2010

Article Tools

* Image Usage & Resolution